儿童系统性红斑狼疮皮下注射贝利尤单抗的药代动力学、药效学与安全性:多中心开放标签试验
该单臂、多中心、开放标签试验评估活动性SLE儿科患者接受标准治疗基础上皮下注射贝利尤单抗的药代动力学、药效学、安全性和探索性疗效。采用三体重带皮下给药方案,30至<50 kg组第12周观察浓度低于≥50 kg组(几何均值82.8 vs 134 μg/mL),但群体药代动力学预测三体重带总体一致并与成人已确立暴露相符。至第52周,22例中18例(81.8%)SELENA-SLEDAI评分较基线降低≥4分。
要点
- 三体重带皮下给药:≥50 kg 200 mg每周一次,30至<50 kg每10天一次,15至<30 kg每2周一次。
- 30至<50 kg组第12周观察浓度低于≥50 kg组(几何均值82.8 vs 134 μg/mL),群体药代动力学预测三体重带总体一致。
- 至第52周,22例中18例(81.8%)SELENA-SLEDAI评分较基线降低≥4分。
核心结论
- 儿科患者皮下注射贝利尤单抗后的暴露与已批准用法一致,安全性和疗效数据一致,支持皮下贝利尤单抗用于儿科SLE患者。
研究设计与样本
- 单臂、多中心、开放标签试验(GSK研究200908;ClinicalTrials.gov NCT04179032),采用三体重带皮下贝利尤单抗给药。
- 药代动力学通过第12周观察浓度及基于52周浓度建立的群体药代动力学(popPK)估计来表征。
- 药效学、安全性和探索性疗效(SELENA-SLEDAI评分较基线降低≥4分)进行描述性评价。
- 另模拟两体重带皮下给药方案(≥40 kg:200 mg每周一次;15至<40 kg:200 mg每2周一次)以预测其药代动力学。
主要发现
- 30至<50 kg组第12周观察贝利尤单抗浓度低于≥50 kg组(几何均值82.8 vs 134 μg/mL)。
- popPK分析预测三体重带总体一致,并与成人已确立的皮下及儿科静脉暴露相符。
- 药效学与安全性特征与已知贝利尤单抗效应一致。
- 至第52周,22例中18例(81.8%)SELENA-SLEDAI评分较基线降低≥4分。
- 模拟的两体重带给药方案预测各体重带暴露一致,并与SLE已确立暴露相符。
关键数值与推荐
- 皮下贝利尤单抗200 mg:体重≥50 kg每周一次(qw);30至<50 kg每10天一次;15至<30 kg每2周一次(q2w)。
- 探索性疗效定义为SELENA-SLEDAI评分较基线降低≥4分。
- 30至<50 kg组第12周观察浓度几何均值82.8 μg/mL vs ≥50 kg组134 μg/mL。
- 模拟两体重带方案:≥40 kg 200 mg每周一次;15至<40 kg 200 mg每2周一次。
临床怎么用
- 儿科活动性SLE患者在标准治疗基础上可考虑皮下贝利尤单抗,采用三体重带给药方案。
- 30至<50 kg组观察浓度较低但popPK预测与成人暴露一致,模拟两体重带方案预测暴露一致。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. METHODS: This single-arm, multicenter, open-label trial (GSK study 200908; ClinicalTrials.gov identifier: NCT04179032) used three-weight-band subcutaneous dosing of belimumab 200 mg every week (qw) for pediatric patients weighing ≥50 kg, every 10 days for pediatric patients weighing 30 to <50 kg, and every 2 weeks (q2w) for pediatric patients weighing 15 to <30 kg. The pharmacokinetic profile was characterized by observed concentration at week 12 and population pharmacokinetics (popPK) estimates derived from concentrations over 52 weeks. Pharmacodynamics, safety, and exploratory efficacy (≥4-point reduction from the baseline Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index [SELENA-SLEDAI] score) were descriptively evaluated. Alternative two-weight-band subcutaneous dosing (≥40 kg: 200 mg qw; 15 to <40 kg: 200 mg q2w) was simulated to predict pharmacokinetics for this regimen. RESULTS: Patients weighing 30 to <50 kg had lower observed belimumab concentrations than those weighing ≥50 kg (week 12 geometric mean 82.8 vs 134 μg/mL), but popPK analyses predicted the three weight bands to be generally consistent and in alignment with established adult subcutaneous and pediatric intravenous exposures. The pharmacodynamic and safety profile was consistent with known belimumab effects. By week 52, 18 of 22 patients (81.8%) had a ≥4-point reduction from baseline SELENA-SLEDAI scores. Hypothetical two-weight-band dosing simulations predicted consistent exposure across weight bands and in line with established exposures in SLE. CONCLUSION: Exposure following subcutaneous belimumab administration in pediatric patients is consistent with approved usage; these findings, along with consistent safety and efficacy data, support subcutaneous belimumab use for pediatric patients with SLE.
引用
- Brunner HI, Antón J, Calvo-Penadés I, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial. Arthritis Care Res (Hoboken). 2026. PMID: 41261055. doi:10.1002/acr.25700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。